Key statistics
On Friday, Biontech SE (22UA:HAM) closed at 90.75, 25.09% above the 52 week low of 72.55 set on Apr 07, 2025.
52-week range
| Open | 89.40 |
|---|---|
| High | 91.25 |
| Low | 89.40 |
| Bid | 89.20 |
| Offer | 91.10 |
| Previous close | 90.05 |
| Average volume | 478.60 |
|---|---|
| Shares outstanding | 259.03m |
| Free float | 233.52m |
| P/E (TTM) | -- |
| Market cap | 27.34bn USD |
| EPS (TTM) | -2.77 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 16:25 GMT.
More ▼
- BioNTech ernennt Kylie Jimenez zur neuen Personalvorständin
- BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
- J.P. Morgan Healthcare Conference: signals for a re-rating of the sector are gaining momentum
- BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference
- BioNTech präsentiert auf der 44. J.P. Morgan Healthcare-Konferenz Updates zur Geschäftsentwicklung und Schwerpunkte für das Jahr 2026
- BioNTech schließt Übernahme von CureVac N.V. samt damit verbundener Nachangebotsfrist ab und stärkt so die einzigartige Position im mRNA-Feld
- BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
- BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
- Erste Ergebnisse aus BioNTechs und BMS’ globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig zeigten ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem dreifach negativem Brustkrebs
- BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
More ▼
